3,4,5-tris(4-methoxyphenyl)-1-methyl-1H-pyrazole | 1314594-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3,4,5-tris(4-methoxyphenyl)-1-methyl-1H-pyrazole
• 英文别名: 3,4,5-Tris(4-methoxyphenyl)-1-methylpyrazole
• CAS: 1314594-79-0
• 化学式: C₂₅H₂₄N₂O₃
• 分子量: 400.477
• InChiKey: RHWZGJSMKGAOFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲氧基苯硼酸 、 1-methyl-3,4,5-tribromopyrazole 在 2-双环己基膦-2',6'-二甲氧基联苯 、 palladium diacetate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 8.5h， 以81%的产率得到3,4,5-tris(4-methoxyphenyl)-1-methyl-1H-pyrazole
  参考文献：
  名称：

  Suzuki–Miyaura reactions of N-protected tribromopyrazoles. Efficient and site-selective synthesis of 3,4,5-triaryl-pyrazoles, 3,5-diaryl-4-bromopyrazoles and 5-aryl-3,4-dibromopyrazoles

  摘要：

  Suzuki-Miyaura reactions of N-protected tribromopyrazoles were studied. The reactions proceed with excellent site-selectivity. The first attack occurs at position 5, while the second and third attack occur at positions 3 and 4, respectively. A variety of 3,4,5-triaryl-pyrazoles, 3,5-diaryl-4-bromopyrazoles, and 5-aryl-3,4-dibromopyrazoles were efficiently prepared. The products are not readily available by other methods. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.05.036

文献信息

• Estrogen receptor modulators
  申请人：CHIRON CORPORATION

  公开号：US20040077701A1

  公开（公告）日：2004-04-22

  Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

  本文描述了调节雌激素受体的吡唑化合物，以及用于治疗或预防雌激素受体介导的疾病的方法和组合物。所述化合物已被发现具有意外和惊人的调节雌激素受体活性的活性。因此，本发明的化合物在预防或治疗雌激素受体介导的疾病，如骨质疏松症、乳腺和子宫内膜癌、动脉硬化和阿尔茨海默病中具有实用性。
• ESTROGEN RECEPTOR MODULATORS
  申请人：Chiron Corporation

  公开号：US20040034081A9

  公开（公告）日：2004-02-19

  Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

  本文描述了调节雌激素受体的吡唑类化合物，以及用于治疗或预防雌激素受体介导的疾病的方法和组合物。所述化合物已被发现具有意外和惊人的调节雌激素受体活性的活性。因此，本发明的化合物在预防或治疗雌激素受体介导的疾病，如骨质疏松症、乳腺和子宫内膜癌、动脉粥样硬化和阿尔茨海默病中具有实用价值。
• PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS
  申请人：CHIRON CORPORATION

  公开号：EP1102753A2

  公开（公告）日：2001-05-30
• US6291505B1
  申请人：——

  公开号：US6291505B1

  公开（公告）日：2001-09-18
• US6727273B2
  申请人：——

  公开号：US6727273B2

  公开（公告）日：2004-04-27